Neuropathology Core

神经病理学核心

• 批准号: 10643933
• 负责人: THOMAS M WISNIEWSKI
• 金额: $ 23.17万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10643933
• 关键词: Acceleration; Address; Alzheimer' s Disease; Alzheimer' s disease related dementia; Animal Model; Autopsy; Biological Markers; Blood Vessels; Brain; Cell Line; Cell model; Clinical; Collaborations; Collection; Communities; Data; Dementia; Diagnosis; Diagnostic; Education and Outreach; Enrollment; Evaluation; Family; Health Professional; Heterogeneity; Image; Impaired cognition; International; Intervention; Measures; Methods; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Participant; Pathogenesis; Pathology; Patients; Procedures; Property; Proteomics; Protocols documentation; Reporting; Research; Research Personnel; Resources; Risk; Sampling; Source; Standardization; Syndrome; System; Technology; Therapeutic; Tissue Sample; Tissues; Training; Work; brain tissue; disease heterogeneity; induced pluripotent stem cell; innovation; laboratory facility; mild cognitive impairment; neuroimaging; neuropathology; new therapeutic target; next generation; normal aging; novel; novel diagnostics; novel therapeutic intervention; prevent; programs; psychosocial; repository; research clinical testing; therapeutically effective; tissue processing

ABSTRACT- NEUROPATHOLOGY CORE The Neuropathology (NP) Core provides for diagnostic neuropathological evaluations of: 1) patients and control subjects enrolled in the Clinical Core (CC), and 2) other clinically well documented patients with neurodegenerative disease. The NP Core aims to enhance understanding of the heterogeneity of AD/ADRD to develop better biomarkers and discover novel and effective therapeutic approaches that promote progress towards achieving the NAPA research implementation milestones. The protocols used by the NP Core will be state of the art and consistent with 21st century brain banking procedures. These will be essential to meet the increasingly sophisticated needs of the AD research community. We will emphasize delineating the presence of overlapping neurodegenerative syndromes. In this renewal, we will continue to emphasize the central theme of the NYU ADRC: elucidating the clinico-pathological substrates that underlie the transitions between normal aging, subjective cognitive decline (SCD), MCI, and dementia to help develop novel interventions that delay or prevent these transitions. The overall objectives of the NP Core of the NYULH ADRC are to provide staff, technical resources, laboratory facilities, and expertise to investigate the structural and molecular properties of the brains of both patients with ADRC and those of normal controls. Aims 1–3 of the NP core encompass the key neuropathology functions of the NP Core. Aims 4 and 5 will develop innovative neuropathological technologies. The emerging clinical evaluation system of ATN—which is proposed to underlie transitional stages between normal aging to SCD, SCD to MCI, and MCI to early dementia—needs to be correlated with comprehensive neuropathological measures that also reflect disease heterogeneity. In addition, while brain tissue is an essential resource, it cannot be developed into dynamic cellular models. Hence, the NP Core has launched a new induced pluripotent stem cell (iPSC) program, providing investigators with an easily replenished source of tissue to address key questions about the heterogeneous pathogenesis of AD/ADRC. Aims 6 and 7 focus on using NP Core resources to train the next generation of neuropathologists and translational neuroscientists conducting research on AD/ADRD, support their studies to develop novel therapeutic targets, and promote educational outreach about brain and biospecimen donation. The combination of these aims will help the NP Core to develop better biomarkers and to discover novel effective, therapeutic approaches; hence, accelerating progress towards achieving the NAPA research implementation milestones.

摘要-神经病理学核心 神经病理学（NP）核心提供以下诊断性神经病理学评价：1）患者和对照组 入组临床核心（CC）的受试者，和2）其他临床记录良好的患者， 神经退行性疾病NP Core旨在加强对AD/ADRD异质性的理解 开发更好的生物标志物，发现新的有效的治疗方法， 努力实现国家适应行动方案研究执行的里程碑。NP Core使用的协议将 是最先进的，并符合21世纪世纪的脑库程序。这些将是必不可少的， 日益复杂的需求的AD研究界。我们将强调描绘的存在， 重叠的神经退行性综合征在这次更新中，我们将继续强调以下中心主题： 纽约大学ADRC：阐明临床病理基础，正常之间的过渡 老化、主观认知下降（SCD）、MCI和痴呆，以帮助开发新的干预措施， 阻止这些转变。NYULH ADRC的NP核心的总体目标是提供工作人员， 研究结构和分子特性的技术资源、实验室设施和专业知识 ADRC患者和正常对照者的大脑。国家方案核心目标1-3包括： NP Core的关键神经病理学功能。目标4和5将发展创新的神经病理学 技术. ATN的新兴临床评价系统-建议作为过渡阶段的基础 正常衰老与SCD、SCD与MCI、MCI与早期痴呆之间的关系需要与 全面的神经病理学测量，也反映了疾病的异质性。此外，虽然大脑 组织是一种重要的资源，它不能发展成动态的细胞模型。因此，NP Core具有 启动了一项新的诱导多能干细胞（iPSC）计划，为研究人员提供了一个容易补充的 组织来源，以解决有关AD/ADRC的异质性发病机制的关键问题。目标6和7 专注于利用NP核心资源培养下一代神经病理学家和翻译 进行AD/ADRD研究的神经科学家，支持他们的研究以开发新的治疗靶点， 并促进有关大脑和生物标本捐赠的教育推广。这些目标的结合将 帮助NP Core开发更好的生物标志物并发现新的有效治疗方法;因此， 加快实现国家适应行动方案研究执行里程碑的进展。